Short-term response to alemtuzumab in CD52-positive secondary histiocytic sarcoma in a child: Is it time to consider new targets?

.

Source: Pediatric Hematology and Oncology - September 7, 2020 Category: Pediatrics Authors: Elvis Terci Valera Mar ía Sol Brassesco Maristella Bergamo Francisco dos Reis Gilberto Maggioni Renato Luiz Guerino-Cunha Carlos Eduardo Grecco Jorge Elias Jr. Mery Kato Luiz Gonzaga Tone Source Type: research